Ticlopidine

Ticlopidine

Systematic (IUPAC) name
5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-cpyridine
Clinical data
Trade names	Ticlid
AHFS/Drugs.com	monograph
MedlinePlus	a695036
Pregnancy cat.	B1 (AU) C (US)
Legal status	?
Routes	Oral
Pharmacokinetic data
Bioavailability	>80%
Protein binding	98%
Metabolism	Hepatic
Half-life	*12 hours (single dose)
Excretion	Renal and fecal
Identifiers
CAS number	55142-85-3 Y
ATC code	B01AC05
PubChem	CID 5472
DrugBank	DB00208
ChemSpider	5273 Y
UNII	OM90ZUW7M1 Y
KEGG	D08594 Y
ChEBI	CHEBI:9588 Y
ChEMBL	CHEMBL833 Y
Chemical data
Formula	C14H14ClNS
Mol. mass	263.786 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 Y Key:PHWBOXQYWZNQIN-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Ticlopidine (trade name Ticlid) is an antiplatelet drug in the thienopyridine family. Like clopidogrel, it is an adenosine diphosphate (ADP) receptor inhibitor. It is used in patients in whom aspirin is not tolerated, or in whom dual antiplatelet therapy is desirable. Because it has been reported to increase the risk of thrombotic thrombocytopenic purpura (TTP) and neutropenia, its use has largely been supplanted by the newer drug, clopidogrel, which is felt to have a much lower hematologic risk. The usual dose is 250 mg twice daily by the oral route.

Action

• Inhibits platelet aggregation by altering the function of platelet membranes by blocking ADP receptors. This prevents the conformational change of glycoprotein IIb/IIIa which allows platelet binding to fibrinogen.
• Prolongs bleeding time.
• Decreased incidence of stroke in high-risk patients.

Contraindications

• Hypersensitivity
• Bleeding disorders
• Active bleeding
• Severe liver disease

Precautions

• Risk of bleeding (trauma, surgery, history of peptic ulcer disease)
• Renal or hepatic impairment
• Geriatric patients (increased sensitivity)
• Pregnancy, lactation, or children under 18
• Neutropenia
• Thrombotic thrombocytopenic purpura